[{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Rubio Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Aspargo Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Aspargo Laboratories"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Vanquish Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Aspargo Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Aspargo Laboratories"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Farmalider SA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Farmalider SA","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Farmalider SA"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Taiba Healthcare"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASP-001","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ASP-001.1","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Aspargo Laboratories

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 12, 2025

                          Lead Product(s) : ASP-001.1

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 20, 2025

                          Lead Product(s) : ASP-001

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 30, 2024

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Sildenafil oral suspension is an oral liquid suspension of sildenafil citrate administered via a metered-dose pump that dispenses 12.5 mg of sildenafil per actuation act as phosphodiesterase-5 inhibitor, which being investigated for the treatment of erec...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2023

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 12, 2023

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 09, 2023

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Hezkue (sildenafil), inhibits cGMP-specific PDE-5. Penile erection involves corpus cavernosum relaxation, mediated by NO and cGMP. The biological actions of cGMP are terminated by phosphodiesterase enzymes and PDE-5 is the major cGMP metabolising enzyme ...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 24, 2023

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 08, 2023

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Sildenafil oral spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push. The discreet and easy-to-carry oral spray allows the user to customize dosing and avoid pill splitting t...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 21, 2022

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Recipient : Vanquish Group

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The license grants Taiba the exclusive right and license to market, promote, and distribute Viagra as Sildenafil Spray in the territory described in the license, which covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Lebanon, ...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 10, 2022

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Taiba Healthcare

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank